The Valley Desk

NCT03113760 · Interventional trial

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Overall registry status Completed

Phase 3

Conditions NLRC4-MAS, XIAP Deficiency

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov